Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Hannelore Denys; Corina L. Martinez-Mena; Marc T. Martens; Randal G. D’Hondt; Marie-Pascale L. Graas; Ella Evron; Georgeta Fried; Noa E. Ben-Baruch; Christof Vulsteke; Mona M. Van Steenberghe

doi:10.1007/s10549-020-05604-7

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05604-7 ◽

2020 ◽

Vol 181 (1) ◽

pp. 97-105 ◽

Cited By ~ 2

Author(s):

Hannelore Denys ◽

Corina L. Martinez-Mena ◽

Marc T. Martens ◽

Randal G. D’Hondt ◽

Marie-Pascale L. Graas ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Home Administration ◽

At Home

Download Full-text

223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2334 ◽

2020 ◽

Vol 31 ◽

pp. S330

Author(s):

A.J. ten Tije ◽

S. van Steenis ◽

J. Briers ◽

E.M.P. Elsten

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Injection Device ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase ◽

Single Use ◽

At Home

Download Full-text

Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

The Breast ◽

10.1016/s0960-9776(17)30116-9 ◽

2017 ◽

Vol 32 ◽

pp. S27

Author(s):

S. Talayeva ◽

D. Kaidarova ◽

E. Zhavrid ◽

A. Prokharau ◽

N. Antonenkova ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Phase Iiib

Download Full-text

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health ◽

10.4274/ejbh.galenos.2021.2021-9-9 ◽

2022 ◽

Vol 18 (1) ◽

pp. 63-73

Author(s):

İrfan Cicin ◽

Mohammed Oukkal ◽

Hassen Mahfouf ◽

Amel Mezlini ◽

Blaha Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Patient Satisfaction ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Phase Iiib

Download Full-text

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

European Journal of Cancer ◽

10.1016/s0959-8049(18)30535-5 ◽

2018 ◽

Vol 92 ◽

pp. S102-S103 ◽

Cited By ~ 1

Author(s):

I. Ciçin ◽

M. Oukkal ◽

H. Mahfouf ◽

A. Mezlini ◽

B. Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Adjuvant Setting ◽

Her2 Positive ◽

Open Label ◽

Safety And Efficacy ◽

Phase Iiib

Download Full-text

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

10.1158/1538-7445.sabcs16-p4-21-17 ◽

2017 ◽

Cited By ~ 2

Author(s):

VF Cocquyt ◽

CL Martinez-Mena ◽

MT Martens ◽

RG D'Hondt ◽

M-PL Graas ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Home Administration ◽

At Home

Download Full-text

An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies

Annals of Oncology ◽

10.1093/annonc/mdw364.66 ◽

2016 ◽

Vol 27 ◽

pp. vi63

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Early Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase Iiib ◽

Cancer Studies

Download Full-text

The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

European Journal of Cancer ◽

10.1016/s0959-8049(18)30542-2 ◽

2018 ◽

Vol 92 ◽

pp. S105-S106

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Early Breast Cancer ◽

Safety Data ◽

Metastatic Breast ◽

Pooled Analysis ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Phase Iiib

Download Full-text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00122-4 ◽

2021 ◽

Author(s):

José Manuel Pérez-García ◽

Geraldine Gebhart ◽

Manuel Ruiz Borrego ◽

Agostina Stradella ◽

Begoña Bermejo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Fdg Pet ◽

Pathological Response ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

18F Fdg

Download Full-text

Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer Patients

Annals of Oncology ◽

10.1016/s0923-7534(20)32833-7 ◽

2012 ◽

Vol 23 ◽

pp. ix102-ix103

Author(s):

C. Jackisch ◽

M. Dank ◽

G. Frasci ◽

K.H. Park ◽

R.I. Lopez ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

International Study ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Additional Safety

Download Full-text

Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study

10.1158/1538-7445.sabcs19-p1-18-05 ◽

2020 ◽

Author(s):

Sherko Kümmel ◽

Carlo A Tondini ◽

Jacinta Abraham ◽

Zbigniew Nowecki ◽

Bartosz Itrych ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Final Analysis ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib

Download Full-text